Immutep's phase 3 trial of its LAG-3 candidate, eftilagimod alfa, in combination with Merck's Keytruda for non-small cell lung cancer unexpectedly failed, leading to an 80% drop in the company's stock and prompting a comprehensive review of the study data to determine future steps.
The unexpected phase 3 failure of Immutep's LAG-3 candidate highlights the inherent risk in drug development, especially in immunotherapy, where promising early-stage results can still lead to later-stage disappointments. For those tracking investment signals in biotech and health startups, this serves as a critical reminder to diversify portfolios and maintain cautious optimism, even when early trial data appears promising. Additionally, it underscores the importance of robust data monitoring and the ability to pivot strategies based on comprehensive data analysis and operational assessments.